<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35581617</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2474</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC musculoskeletal disorders</Title>
          <ISOAbbreviation>BMC Musculoskelet Disord</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway.</ArticleTitle>
        <Pagination>
          <StartPage>465</StartPage>
          <MedlinePgn>465</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">465</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12891-022-05396-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Diabetes-associated osteoporosis are partly caused by accumulation of advanced glycation endproducts (AGEs). Glucagon-like peptide-1 (GLP-1) has been shown to regulate bone turnover. Here we explore whether GLP-1 receptor agonist (GLP1RA) can have a beneficial effect on bone in diabetes by ameliorating AGEs.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In the present study, we evaluated the effects of the GLP-1 receptor agonist liraglutide, insulin and dipeptidyl peptidase-4 inhibitor saxagliptin on Zucker diabetic fatty rats. Meanwhile, we observed the effect of GLP-1 on AGEs-mediated osteoblast proliferation and differentiation and the signal pathway.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Liraglutide prevented the deterioration of trabecular microarchitecture and enhanced bone strength. Moreover, it increased serum Alpl, Ocn and P1NP levels and decreased serum CTX. In vitro we confirmed that GLP-1 could attenuate AGEs-mediated damage in osteogenic proliferation and differentiation. Besides, GLP-1 down-regulated the ROS that caused by AGEs and the mRNA and protein expression of Rage .</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Altogether, our findings suggest that GLP-1 receptor agonist promotes osteoblastogenesis and suppresses bone resorption on obese type 2 diabetic rats to a certain degree. The mechanism of these effects may be partly mediated by AGEs-RAGE-ROS pathway via the interaction with GLP-1 receptor.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Cheng</LastName>
            <ForeName>Yanzhen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiang</LastName>
            <ForeName>Qianru</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Jiamin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Huafeng</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hua</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China. jimzhua@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nutrition, Zhujiang Hospital, the Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, People's Republic of China. yangli19762009@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Musculoskelet Disord</MedlineTA>
        <NlmUniqueID>100968565</NlmUniqueID>
        <ISSNLinking>1471-2474</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>839I73S42A</RegistryNumber>
          <NameOfSubstance UI="D000069450">Liraglutide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>89750-14-1</RegistryNumber>
          <NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003921" MajorTopicYN="Y">Diabetes Mellitus, Experimental</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052216" MajorTopicYN="N">Glucagon-Like Peptide 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName>
          <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069450" MajorTopicYN="N">Liraglutide</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010024" MajorTopicYN="Y">Osteoporosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011924" MajorTopicYN="N">Rats, Zucker</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Advanced glycation endproducts</Keyword>
        <Keyword MajorTopicYN="N">Diabetes</Keyword>
        <Keyword MajorTopicYN="N">Glucagon-like peptide-1</Keyword>
        <Keyword MajorTopicYN="N">Liraglutide</Keyword>
        <Keyword MajorTopicYN="N">Osteoporosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>23</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35581617</ArticleId>
        <ArticleId IdType="pmc">PMC9112483</ArticleId>
        <ArticleId IdType="doi">10.1186/s12891-022-05396-5</ArticleId>
        <ArticleId IdType="pii">10.1186/s12891-022-05396-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pignolo RJ, Law SF, Chandra A. Bone aging, cellular senescence, and osteoporosis. JBMR Plus. 2021;5(4):e10488. doi: 10.1002/jbm4.10488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbm4.10488</ArticleId>
            <ArticleId IdType="pmc">PMC8046105</ArticleId>
            <ArticleId IdType="pubmed">33869998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gribble FM, Reimann F. Metabolic messengers: glucagon-like peptide 1. Nat Metab. 2021;3(2):142–148. doi: 10.1038/s42255-020-00327-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42255-020-00327-x</ArticleId>
            <ArticleId IdType="pubmed">33432200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jorgensen NR, et al.  GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocr Metab. 2015;100(8):2909–2917. doi: 10.1210/jc.2015-1176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2015-1176</ArticleId>
            <ArticleId IdType="pubmed">26043228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474–2476. doi: 10.2337/dc11-1099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc11-1099</ArticleId>
            <ArticleId IdType="pmc">PMC3198283</ArticleId>
            <ArticleId IdType="pubmed">22025784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M, Sugimoto T. Advanced Glycation end products, diabetes, and bone strength. Curr Osteoporos Rep. 2016;14(6):320–326. doi: 10.1007/s11914-016-0332-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11914-016-0332-1</ArticleId>
            <ArticleId IdType="pmc">PMC5104767</ArticleId>
            <ArticleId IdType="pubmed">27704396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Yin L, Xu Z, An FM, Liu AR, Wang Y, et al. Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis. Neurosci Lett. 2016:612–193, 8. 10.1016/j.neulet.2015.12.007.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang S, Lin C, Zhuo X, Wang J, Rao S, Xu W, et al.  Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway. Am J Physiol Endocrinol Metab. 2020;319(6):E1019–E1E30. doi: 10.1152/ajpendo.00195.2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00195.2019</ArticleId>
            <ArticleId IdType="pubmed">32985256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Yang L, Lei L, Chen R, Chen H, Zhang H. Glucagon-like peptide-1 attenuates advanced oxidation protein product-mediated damage in islet microvascular endothelial cells partly through the RAGE pathway. Int J Mol Med. 2016;38(4):1161–1169. doi: 10.3892/ijmm.2016.2711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2016.2711</ArticleId>
            <ArticleId IdType="pmc">PMC5029952</ArticleId>
            <ArticleId IdType="pubmed">27574116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nephan G, Coskun ZM, Bolkent S. Dipeptidyl peptidase-4 inhibition prevents cell death via extrinsic and intrinsic apoptotic pathways in rat pancreas with insulin resistance. Cell Biochem Funct. 2018;36(4):212–220. doi: 10.1002/cbf.3333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbf.3333</ArticleId>
            <ArticleId IdType="pubmed">29748970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou R, Lin C, Cheng Y, Zhuo X, Li Q, Xu W, et al.  Liraglutide alleviates hepatic Steatosis and liver injury in T2MD rats via a GLP1R dependent AMPK pathway. Front Pharmacol. 2020;11:600175. doi: 10.3389/fphar.2020.600175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.600175</ArticleId>
            <ArticleId IdType="pmc">PMC7970416</ArticleId>
            <ArticleId IdType="pubmed">33746742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng YZ, Yang SL, Wang JY, Ye M, Zhuo XY, Wang LT, et al.  Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sci. 2018;205:184–192. doi: 10.1016/j.lfs.2018.04.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2018.04.042</ArticleId>
            <ArticleId IdType="pubmed">29702126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petito-da-Silva TI, Souza-Mello V, Barbosa-da-Silva S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol Cell Endocrinol. 2019;498:110539. doi: 10.1016/j.mce.2019.110539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2019.110539</ArticleId>
            <ArticleId IdType="pubmed">31419466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang JY, Cheng YZ, Yang SL, An M, Zhang H, Chen H, et al.  Dapagliflozin attenuates hyperglycemia related osteoporosis in ZDF rats by alleviating hypercalciuria. Front Endocrinol (Lausanne) 2019;10:700. doi: 10.3389/fendo.2019.00700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2019.00700</ArticleId>
            <ArticleId IdType="pmc">PMC6856656</ArticleId>
            <ArticleId IdType="pubmed">31781028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Li P, Tang Z, Dou Q, Feng B. Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE(−/−) mice. Ann Transl Med. 2019;7(16):369. doi: 10.21037/atm.2019.06.74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm.2019.06.74</ArticleId>
            <ArticleId IdType="pmc">PMC6736830</ArticleId>
            <ArticleId IdType="pubmed">31555683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao CH, Liang J, Yang YQ, Yu MX, Qu XH. The impact of glucagon-like Peptide-1 on bone metabolism and its possible mechanisms. Front Endocrinol. 2017;8. 10.3389/fendo.2017.00098.</Citation>
        </Reference>
        <Reference>
          <Citation>Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, Moreno P, Marinoso ML, Esbrit P, et al.  GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol. 2011;209(2):203–210. doi: 10.1530/JOE-11-0015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JOE-11-0015</ArticleId>
            <ArticleId IdType="pubmed">21372151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunck MC, Eliasson B, Corner A, Heine RJ, Shaginian RM, Taskinen MR, et al.  Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):374–377. doi: 10.1111/j.1463-1326.2010.01355.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2010.01355.x</ArticleId>
            <ArticleId IdType="pubmed">21205127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen LB, Kollerup G, Quaade F, Sorensen OH. Bone minerals changes in obese women during a moderate weight loss with and without calcium supplementation. J Bone Miner Res. 2001;16(1):141–147. doi: 10.1359/jbmr.2001.16.1.141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1359/jbmr.2001.16.1.141</ArticleId>
            <ArticleId IdType="pubmed">11149478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone. 2002;30(1):307–313. doi: 10.1016/s8756-3282(01)00662-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s8756-3282(01)00662-7</ArticleId>
            <ArticleId IdType="pubmed">11792602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng YY, Su L, Zhong X, Wei GH, Xiao HP, Li YB, et al.  Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation. J Mol Endocrinol. 2016;56(3):189–199. doi: 10.1530/JME-15-0264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JME-15-0264</ArticleId>
            <ArticleId IdType="pubmed">26647389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JY, Lee SK, Jo KJ, Song DY, Lim DM, Park KY, et al.  Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci. 2013;92(10):533–540. doi: 10.1016/j.lfs.2013.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2013.01.001</ArticleId>
            <ArticleId IdType="pubmed">23357248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun HX, Lu N, Luo X, Zhao L, Liu JM. Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats. J Diabetes. 2015;7(4):584–588. doi: 10.1111/1753-0407.12282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1753-0407.12282</ArticleId>
            <ArticleId IdType="pubmed">25753217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islam MS, Venkatesan V. Experimentally-induced animal models of Prediabetes and insulin resistance: a review. Acta Pol Pharm. 2016;73(4):827–834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29648707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsuda Y, Ohta T, Miyajima K, Kemmochi Y, Sasase T, Tong B, et al.  Diabetic complications in obese type 2 diabetic rat models. Exp Anim Tokyo. 2014;63(2):121–132. doi: 10.1538/expanim.63.121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1538/expanim.63.121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuan L, SQ S, YY S, xx  Clinical observation of saxagliptin on bone metabolism in patients with type 2 diabetes mellitus. J Aerospace Med. 2019;30(03):312–314.</Citation>
        </Reference>
        <Reference>
          <Citation>Kyle KA, Willett TL, Baggio LL, Drucker DJ, Grynpas MD. Differential effects of PPAR-gamma activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology. 2011;152(2):457–467. doi: 10.1210/en.2010-1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2010-1098</ArticleId>
            <ArticleId IdType="pmc">PMC3084690</ArticleId>
            <ArticleId IdType="pubmed">21177828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bock G, Man CD, Micheletto F, Basu R, Giesler PD, Laugen J, et al.  The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol. 2010;73(2):189–196. doi: 10.1111/j.1365-2265.2009.03764.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2009.03764.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman GA, Bergman A, Stevens C, Kotey P, Yi BM, Zhao P, et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocr Metab. 2006;91(11):4612–4619. doi: 10.1210/jc.2006-1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2006-1009</ArticleId>
            <ArticleId IdType="pubmed">16912128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. Biochemical markers of bone turnover as predictors of osteoporosis and osteoporotic fractures in men and women: 10-year follow-up of the Taiji cohort. Mod Rheumatol. 2011;21(6):608–620. doi: 10.3109/s10165-011-0455-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/s10165-011-0455-2</ArticleId>
            <ArticleId IdType="pubmed">21512822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuche-Berenguer B, Moreno P, Esbrit P, Dapia S, Caeiro JR, Cancelas J, et al.  Effect of GLP-1 treatment on bone turnover in Normal, type 2 diabetic, and insulin-resistant states. Calcified Tissue Int. 2009;84(6):453–461. doi: 10.1007/s00223-009-9220-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00223-009-9220-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 2006;99(5):1233–1239. doi: 10.1002/jcb.20958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcb.20958</ArticleId>
            <ArticleId IdType="pubmed">16795049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dejgaard TF, Johansen NB, Frandsen CS, Asmar A, Tarnow L, Knop FK, et al.  Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes Obes Metab. 2017;19(5):734–738. doi: 10.1111/dom.12841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.12841</ArticleId>
            <ArticleId IdType="pubmed">27935240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318(20):1315–1321. doi: 10.1056/NEJM198805193182007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198805193182007</ArticleId>
            <ArticleId IdType="pubmed">3283558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251(2):87–101. doi: 10.1046/j.1365-2796.2002.00932.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2796.2002.00932.x</ArticleId>
            <ArticleId IdType="pubmed">11905595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11(18):2279–2299. doi: 10.2174/1381612054367300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612054367300</ArticleId>
            <ArticleId IdType="pubmed">16022668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res. 1996;11(7):931–937. doi: 10.1002/jbmr.5650110709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbmr.5650110709</ArticleId>
            <ArticleId IdType="pubmed">8797113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katayama Y, Celic S, Nagata N, Martin TJ, Findlay DM. Nonenzymatic glycation of type I collagen modifies interaction with UMR 201-10B preosteoblastic cells. Bone. 1997;21(3):237–242. doi: 10.1016/s8756-3282(97)00128-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s8756-3282(97)00128-2</ArticleId>
            <ArticleId IdType="pubmed">9276088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011;12(14):2096–2102. doi: 10.2174/138945011798829456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138945011798829456</ArticleId>
            <ArticleId IdType="pubmed">22023404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, et al.  Regulation of osteoclast function and bone mass by RAGE. J Exp Med. 2006;203(4):1067–1080. doi: 10.1084/jem.20051947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20051947</ArticleId>
            <ArticleId IdType="pmc">PMC2118287</ArticleId>
            <ArticleId IdType="pubmed">16606672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cepas V, Collino M, Mayo JC, Sainz RM. Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases. Antioxidants (Basel). 2020;9(2). 10.3390/antiox9020142.</Citation>
        </Reference>
        <Reference>
          <Citation>Wautier MP, Guillausseau PJ, Wautier JL. Activation of the receptor for advanced glycation end products and consequences on health. Diabetes Metab Syndr. 2017;11(4):305–309. doi: 10.1016/j.dsx.2016.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dsx.2016.09.009</ArticleId>
            <ArticleId IdType="pubmed">27612394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rai V, Maldonado AY, Burz DS, Reverdatto S, Yan SF, Schmidt AM, et al.  Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem. 2012;287(14):11283. doi: 10.1074/jbc.M111.277731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.277731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonichen A, Geyer M. Fifteen formins for an actin filament: a molecular view on the regulation of human formins. Bba-Mol. Cell Res. 2010;1803(2):152–163. doi: 10.1016/j.bbamcr.2010.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2010.01.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiller HB, Hermann MR, Polleux J, Vignaud T, Zanivan S, Friedel CC, et al.  beta1- and alphav-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat Cell Biol. 2013;15(6):625–636. doi: 10.1038/ncb2747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb2747</ArticleId>
            <ArticleId IdType="pubmed">23708002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudson BI, Kalea AZ, Del Mar AM, Harja E, Boulanger E, D’Agati V, et al.  Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008;283(49):34457–34468. doi: 10.1074/jbc.M801465200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M801465200</ArticleId>
            <ArticleId IdType="pmc">PMC2590709</ArticleId>
            <ArticleId IdType="pubmed">18922799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, et al.  Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004;109(2):227–233. doi: 10.1161/01.CIR.0000105680.92873.70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000105680.92873.70</ArticleId>
            <ArticleId IdType="pubmed">14718399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piwkowska A, Rogacka D, Kasztan M, Angielski S, Jankowski M. Insulin increases glomerular filtration barrier permeability through dimerization of protein kinase G type Ialpha subunits. Biochim Biophys Acta. 2013;1832(6):791–804. doi: 10.1016/j.bbadis.2013.02.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2013.02.011</ArticleId>
            <ArticleId IdType="pubmed">23454089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng D, Mei A, Liu J, Kang X, Shi X, Qian R, et al.  NADPH oxidase 4 mediates insulin-stimulated HIF-1alpha and VEGF expression, and angiogenesis in vitro. PLoS One. 2012;7(10):e48393. doi: 10.1371/journal.pone.0048393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0048393</ArticleId>
            <ArticleId IdType="pmc">PMC3483150</ArticleId>
            <ArticleId IdType="pubmed">23144758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He WT, Liu K, Sun JX, Shi XL. Recent progress on the researches of cathepsin k and treatment of osteoporosis disease. Chinese. J Osteoporos. 2008;14(9):670–673. doi: 10.3969/j.issn.1006-7108.2008.09.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3969/j.issn.1006-7108.2008.09.016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Weng J, Xu J, Xu Q, Wang W, Zhang W, et al.  Mdia1 is crucial for advanced Glycation end product-induced endothelial Hyperpermeability. Cell Physiol Biochem. 2018;45(4):1717–1730. doi: 10.1159/000487780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000487780</ArticleId>
            <ArticleId IdType="pubmed">29490301</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
